At the 2025 North American Cystic Fibrosis Conference, Sionna Therapeutics presented Phase 1 data for their NBD1 stabilizers, SION-719 and SION-451, which showed they were well tolerated and met pharmacokinetic targets. The new preclinical data revealed that these stabilizers restored the half-life of F508del-CFTR protein to wild-type levels. Sionna is focused on advancing therapies for CF, with ongoing trials expected to deliver results in mid-2026. The company is developing novel medicines to normalize CFTR protein function, aiming to improve clinical outcomes and quality of life for CF patients. Their work has the potential to revolutionize CF treatment.

Read more at GlobeNewswire: Sionna Therapeutics Announces Presentation of SION-719 and